

From Palm Tocotrienol-Rich Fractions to Precision Metabolic Therapy: Tocotrienols in Type 2 Diabetes, Redox Biology, miRNA Signaling, and the Translational Gap

Loso Judijanto*

IPOSS Jakarta, Indonesia.

ORCID : 0009-0007-7766-0647

*Correspondence:

Loso Judijanto, IPOSS Jakarta, Indonesia.

Received: 15 Aug 2026; Accepted: 16 Sep 2026; Published: 29 Sep 2026

Citation: Loso Judijanto. From Palm Tocotrienol-Rich Fractions to Precision Metabolic Therapy: Tocotrienols in Type 2 Diabetes, Redox Biology, miRNA Signaling, and the Translational Gap. *Endocrinol Metab Nutr.* 2026; 5(3): 1-13.

ABSTRACT

Type 2 diabetes mellitus (T2DM) is a heterogeneous metabolic disease characterized by insulin resistance, progressive β -cell dysfunction, chronic hyperglycemia, oxidative stress, mitochondrial impairment, low-grade inflammation, dyslipidemia, endothelial dysfunction, and cumulative microvascular and macrovascular injury. Tocotrienols, unsaturated members of the vitamin E family, have attracted interest as multi-target bioactives capable of influencing several of these mechanisms simultaneously. This qualitative literature review critically evaluates evidence on palm-derived tocotrienol-rich fractions (TRF) and related tocotrienol formulations in T2DM, emphasizing glycemic control, insulin resistance, oxidative and inflammatory pathways, advanced glycation, endothelial biology, diabetic complications, and microRNA regulation. Human trials indicate potentially favorable effects on HbA1c and insulin resistance, while studies of diabetic kidney disease and peripheral neuropathy suggest organ-specific biological activity. Nevertheless, intervention heterogeneity is substantial, and the prominent trial demonstrating simultaneous glycemic, inflammatory, oxidative, and miRNA effects used an annatto-derived δ/γ -tocotrienol formulation rather than palm-derived TRF. Current evidence therefore supports biological plausibility rather than definitive disease modification. Future development requires standardized botanical provenance and isoform composition, pharmacokinetic verification, longer multicenter trials, contemporary cardiorenal background therapy, continuous glucose monitoring, complication-specific endpoints, and integration of metabolomics, lipidomics, epigenomics, and miRNA profiling. Tocotrienols are best positioned as investigational adjunctive nutraceuticals within precision metabolic care rather than alternatives to established diabetes therapies.

Keywords

Tocotrienol, Palm oil, Tocotrienol-rich fraction, Type 2 diabetes, Insulin resistance, Oxidative stress, Inflammation, MicroRNA, Diabetic complications, Precision nutrition.

JEL Classification: I10; I12; I15; Q16; Q18

Introduction

Type 2 diabetes mellitus (T2DM) has become one of the defining metabolic health challenges of the twenty-first century. The Global Burden of Disease Study estimated that 529 million people were living with diabetes in 2021, with T2DM accounting for approximately 96% of cases; projections suggest that more than 1.3 billion people could be affected by 2050 if prevailing demographic,

obesity, dietary, and socioeconomic trajectories persist. The burden extends far beyond abnormal glucose concentrations because T2DM contributes substantially to cardiovascular disease, chronic kidney disease, neuropathy, retinopathy, disability, premature mortality, and escalating healthcare expenditure. High body mass index remains a major attributable driver, but substantial variation in disease phenotype and progression occurs among populations and individuals, underscoring the limitations of treating T2DM as a uniform metabolic disorder [1-3]. Recent precision-diabetes frameworks emphasize that a glucose-defined diagnosis conceals substantial etiological, pathophysiological, and prognostic heterogeneity, strengthening the case for response-stratified adjunctive interventions [4,5].

The pathophysiology of T2DM extends substantially beyond persistent hyperglycemia. Insulin resistance in skeletal muscle, liver, and adipose tissue initially increases the secretory demand placed on pancreatic β -cells. Compensatory hyperinsulinemia can temporarily maintain glucose homeostasis, but chronic nutrient excess, lipotoxicity, glucotoxicity, endoplasmic-reticulum stress, oxidative stress, mitochondrial dysfunction, inflammatory signaling, and genetic susceptibility progressively impair β -cell function. Consequently, T2DM can be understood as a dynamic interaction between resistance to insulin action and a declining capacity of β -cells to compensate for that resistance rather than as a single defect in glucose disposal [6-9].

Contemporary diabetes therapeutics have accordingly moved beyond a glucose-centric model. The current standard of care considers glycemic efficacy together with cardiovascular disease, heart failure, chronic kidney disease, body weight, liver disease, hypoglycemia risk, treatment burden, tolerability, cost, and individual preferences. SGLT2 inhibitors and GLP-1 receptor agonists are now used because of cardiorenal benefits that can be clinically relevant independent of HbA1c, while dual GIP/GLP-1 receptor agonism has further expanded the metabolic treatment landscape. This evolution raises the evidentiary threshold for nutraceutical interventions: a modest reduction in fasting glucose or HbA1c may demonstrate biological activity but is no longer sufficient by itself to establish a clinically meaningful role in modern T2DM care [10-12].

Nevertheless, the complex and interconnected biology of T2DM provides a rationale for investigating adjunctive food-derived bioactive compounds that influence more than one pathogenic pathway. Tocotrienols are particularly interesting in this context. Together with tocopherols, they constitute the vitamin E family, but tocotrienols possess an unsaturated isoprenoid side chain that differentiates their membrane behavior, metabolism, pharmacokinetics, and potentially their biological actions from α -tocopherol. Palm oil is an important natural source, and palm-derived tocotrienol-rich fraction (TRF) generally contains α -, γ -, and δ -tocotrienols together with variable tocopherol. Annatto preparations, by contrast, are typically enriched in δ - and γ -tocotrienol and contain little or no α -tocopherol [13-15].

This source distinction is not merely botanical. It is central to interpretation of the clinical evidence. One of the most informative contemporary T2DM randomized trials administered 250 mg/day δ -tocotrienol for 24 weeks and reported reductions in plasma glucose, insulin, HOMA-IR, HbA1c, malondialdehyde, hs-CRP, TNF- α , and IL-6, accompanied by changes in selected circulating microRNAs. Yet the formulation was annatto-derived rather than palm-derived TRF. Conversely, studies evaluating diabetic kidney disease and diabetic neuropathy have used Tocovid, a palm-derived tocotrienol-rich vitamin E formulation. Thus, a scientifically rigorous review must distinguish direct palm evidence from broader tocotrienol-class evidence rather than merging all formulations under the labels “tocotrienol” or “vitamin E” [16-19].

The available evidence is simultaneously encouraging and cautionary. A 2023 systematic review and meta-analysis of 10 randomized trials involving 754 participants with T2DM estimated a modest pooled HbA1c reduction of approximately 0.23 percentage points with TRF supplementation. The effect appeared larger in studies lasting less than six months and among participants with diabetes duration shorter than 10 years, whereas pooled effects on blood pressure and hs-CRP were not statistically significant. These findings raise a more sophisticated question than whether tocotrienols “work”: responsiveness may depend on disease duration, baseline phenotype, formulation, isoform profile, systemic exposure, and concurrent therapy [20,21].

This qualitative literature review therefore examines tocotrienols as potential **multi-node metabolic modulators** rather than as simple glucose-lowering antioxidants. It integrates evidence concerning insulin resistance, β -cell dysfunction, oxidative and mitochondrial stress, inflammatory signaling, adipokines, lipid metabolism, endothelial dysfunction, the AGE-RAGE axis, diabetic kidney and nerve complications, and miRNA regulation. Particular attention is given to the distinction between palm-derived TRF and annatto-derived tocotrienols and to the gap between improvements in surrogate biomarkers and clinically meaningful outcomes. The review ultimately asks who might respond to tocotrienol supplementation, which formulation might be responsible, through what mechanisms, and what evidence would be required to incorporate palm-derived tocotrienols credibly into precision metabolic care.

Literature Review: Conceptual and Theoretical Foundations **T2DM as a systems-metabolism disorder**

Traditional descriptions of T2DM often begin with insulin resistance and β -cell dysfunction, but contemporary evidence supports a broader systems-level interpretation. Skeletal-muscle insulin resistance reduces insulin-mediated glucose uptake, hepatic insulin resistance contributes to inappropriate endogenous glucose production, and adipose-tissue insulin resistance increases lipolysis and circulating free fatty acid availability. These abnormalities interact with ectopic lipid deposition, altered incretin biology, glucagon dysregulation, renal glucose handling, inflammatory signaling, and neural mechanisms. The result is a metabolic network in which abnormalities in one tissue propagate to others, explaining why interventions that act upstream on adiposity or insulin resistance can produce widespread metabolic effects [6,22]. A recent pathophysiological framework similarly organizes T2DM heterogeneity around interacting hallmarks that include β -cell dysfunction, insulin resistance, obesity, subclinical inflammation, metabolic dysregulation, hypertension, and prothrombotic biology, reinforcing the need for multi-pathway therapeutic models [23].

β -Cell deterioration is especially important when considering the timing of nutraceutical intervention. β -Cells initially compensate for insulin resistance by increasing insulin secretion, but prolonged metabolic stress may progressively erode both functional capacity and β -cell identity. Clinical phenotypes associated with longer

diabetes duration, severe hyperglycemia, and sustained need for secretagogue therapy often indicate advanced β -cell dysfunction. This provides a plausible explanation for the observation that the pooled HbA1c effect of TRF appeared greater among people with diabetes duration below 10 years: a metabolic modulator that improves insulin sensitivity may be more effective when adequate β -cell reserve remains than when endogenous insulin-secretory capacity is severely compromised [7,8,20].

T2DM heterogeneity is also influenced by ancestry and body-composition phenotype. South and East Asian populations can develop T2DM at lower BMI and may exhibit relatively greater β -cell deficiency, visceral adiposity, or tissue-specific insulin resistance than populations traditionally represented in Western trials. Precision-subclassification studies similarly show reproducible metabolic subgroups that differ in insulin deficiency, insulin resistance, obesity, age at diagnosis, and complication risk. Consequently, future tocotrienol studies conducted in palm-producing Asian countries should not assume that effects observed in one T2DM phenotype will apply uniformly to all patients [2,3].

Oxidative stress, mitochondria, and β -cell vulnerability

Oxidative stress provides a major mechanistic rationale for tocotrienol research. Chronic hyperglycemia increases mitochondrial electron pressure, glucose autooxidation, protein glycation, polyol-pathway activity, and formation of reactive oxygen species (ROS). Excess ROS can oxidize lipids, proteins, and nucleic acids while altering insulin-signaling pathways and activating inflammatory transcription factors. β -Cells are particularly vulnerable because their endogenous antioxidant defenses are relatively limited compared with several other tissues, making persistent oxidative stress a plausible contributor to declining secretory capacity [22,24].

Mitochondrial dysfunction is more than a source of ROS. Mitochondria integrate nutrient oxidation, ATP generation, calcium homeostasis, insulin secretion, and apoptosis. In T2DM, dysfunctional mitochondrial dynamics and impaired mitophagy can allow damaged mitochondria to accumulate, increasing oxidative stress while compromising metabolic flexibility. Autophagy and mitophagy therefore represent critical quality-control mechanisms whose impairment may link nutrient excess to both insulin resistance and β -cell dysfunction. Current knowledge indicates that oxidative stress and mitochondrial dysfunction form reciprocal loops rather than a simple one-directional causal pathway [25,26].

These observations create an important conceptual distinction. If tocotrienols merely neutralized circulating ROS, their effects might resemble nonspecific antioxidant supplementation. If, however, they also influence membrane lipid oxidation, mitochondrial function, inflammatory signaling, lipid metabolism, and transcriptional regulation, they could potentially alter the metabolic environment that generates oxidative stress in the first place. Reviews of tocotrienol biology increasingly favor this broader interpretation, although the mechanistic evidence

remains much stronger in experimental systems than in rigorously phenotyped human T2DM populations [14,27].

Inflammation and the insulin-resistance–vascular interface

T2DM is associated with chronic low-grade inflammation, often termed metaflammation. In adipose tissue, nutrient excess, hypoxia, adipocyte hypertrophy, macrophage recruitment, and altered adipokine secretion can activate inflammatory pathways that interfere with insulin signaling. NF- κ B is central to this process because it regulates transcription of TNF- α , IL-6, and other mediators. The NLRP3 inflammasome provides another mechanism through which metabolic danger signals activate caspase-1, IL-1 β , and IL-18, linking tissue stress to systemic inflammation [28,29].

Inflammation also intersects with vascular injury. Hyperglycemia and insulin resistance impair nitric-oxide bioavailability, increase oxidative stress, promote expression of adhesion molecules, and favor endothelial activation. These processes contribute to atherosclerosis, microvascular dysfunction, and organ injury. Endothelial dysfunction is therefore a plausible intermediate endpoint for nutraceutical research, but the clinical standard must remain high: reductions in inflammatory biomarkers do not automatically imply fewer cardiovascular events [30,31].

Adipokines further connect inflammation, obesity, and insulin resistance. Adiponectin generally promotes fatty-acid oxidation and insulin sensitivity, whereas obesity is frequently accompanied by reduced adiponectin and increased leptin, resistin, and other metabolically unfavorable signals. Newly characterized adipokines, including asprosin, NRG4, and metrn1, illustrate the endocrine complexity of adipose tissue and the difficulty of attributing systemic metabolic improvement to a single pathway [32].

Advanced glycation, endothelial injury, and metabolic memory

Persistent hyperglycemia promotes nonenzymatic glycation of proteins, lipids, and nucleic acids and generates advanced glycation end products (AGEs). Binding of AGEs to the receptor for advanced glycation end products (RAGE) activates signaling pathways including NF- κ B, MAPK, JNK, and TGF- β , thereby reinforcing oxidative stress, inflammation, vascular dysfunction, and tissue fibrosis. AGE–RAGE signaling may also influence pancreatic β -cell toxicity and epigenetic regulation, linking long-term glycemic exposure with the phenomenon sometimes described as metabolic memory [33,34].

Human studies provide evidence that circulating AGEs and their receptor systems are disturbed in diabetes. Indyk et al. found altered AGE and RAGE-related profiles in individuals with T2DM, with associations involving HbA1c and renal-function variables. Such observations are relevant to tocotrienols because lipid peroxidation and glycoxidation share oxidative intermediates; however, direct evidence that palm TRF interrupts AGE–RAGE signaling sufficiently to alter diabetic outcomes remains limited. AGE biomarkers should therefore be considered promising

mechanistic endpoints rather than established surrogate outcomes for tocotrienol therapy [35].

Tocotrienol chemistry, source, and pharmacokinetics

The vitamin E family comprises α -, β -, γ -, and δ -tocopherol and the corresponding four tocotrienols. Tocotrienols differ from tocopherols through an unsaturated farnesyl side chain, which influences mobility within lipid bilayers and may contribute to biological effects not shared equally by α -tocopherol. Evidence suggests that individual tocotrienol isoforms differ in antioxidant, anti-inflammatory, lipid-regulatory, and signaling activity, making the term “vitamin E supplementation” insufficiently precise for mechanistic interpretation [13,14].

Palm-derived TRF is particularly relevant because palm oil contains substantial tocotrienol concentrations. Yet palm TRF is usually a mixture and can contain α -tocopherol, whereas annatto preparations are enriched in δ - and γ -tocotrienol. A pharmacokinetic systematic review comparing annatto-based formulations and palm TRF highlighted variation in absorption, peak concentration, and bioavailability across preparations. Consequently, a clinical effect observed with 250 mg/day of an annatto-derived δ -rich preparation cannot automatically be assumed for 250 mg/day of palm TRF [15,36].

Bioavailability is itself a major translational challenge. Tocotrienols are poorly water soluble, rely on intestinal lipid handling for absorption, and have relatively short circulating half-lives. Food intake, carrier formulation, emulsification technology, tocopherol content, and dose can alter exposure. Nanoformulations, self-

emulsifying systems, and other lipid-based delivery technologies are being developed to overcome these limitations, but improved delivery also changes the intervention and must therefore be evaluated rather than presumed equivalent to conventional formulations [37,38].

As illustrated in Figure 1, botanical source and formulation are foundational to interpreting subsequent clinical evidence. The diagram emphasizes that “tocotrienol” is not a single intervention but a sequence beginning with botanical provenance and ending with systemic exposure and target-tissue response.

The figure illustrates why botanical provenance should be reported alongside nominal dose. Two preparations that both contain “250 mg tocotrienol” may deliver different proportions of δ -, γ -, and α -tocotrienol and therefore yield different plasma concentrations and tissue exposures. Future trials should accordingly measure circulating tocotrienol isoforms whenever possible so that exposure–response relationships can be distinguished from simple dose–response relationships

Method

This article used a **critical qualitative literature review** methodology. It was deliberately designed as a qualitative and interpretive review rather than a systematic literature review or meta-analysis because the evidence relevant to tocotrienols in T2DM spans heterogeneous biological levels, including molecular studies, animal models, randomized clinical trials, studies of diabetic complications, pharmacokinetic research, systematic reviews, meta-analyses, clinical guidelines, and precision-

FIGURE 1 From botanical source to biological exposure




Figure 1: From botanical source to biological exposure: palm TRF versus annatto tocotrienols.

Source: Author's synthesis based on refs. [13,15,36-38].

medicine literature. The objective was therefore to develop an integrated explanatory synthesis rather than quantitatively pool effect sizes.

The principal literature window was January 2020 through August 2026. Searches were conceptually centered on PubMed/MEDLINE, Scopus, Web of Science, and major publisher platforms. Disease-related terms included “type 2 diabetes,” “T2DM,” “prediabetes,” “insulin resistance,” “diabetic kidney disease,” and “diabetic neuropathy”. Intervention terms included “tocotrienol”, “tocotrienol-rich fraction”, “palm tocotrienol”, “palm vitamin E”, “delta-tocotrienol”, “gamma-tocotrienol”, “annatto tocotrienol”, and “Tocovid”. Mechanistic terms included “oxidative stress”, “mitochondria”, “NF-κB”, “NLRP3”, “advanced glycation”, “endothelial dysfunction”, “adipokines”, “microRNA”, “epigenetics”, “metabolomics”, and “precision nutrition”.

Evidence was selected according to relevance to the review's core questions rather than according to a PRISMA-type exhaustive screening framework. Peer-reviewed human randomized trials were given the greatest weight for questions of clinical efficacy. Experimental studies were used to evaluate biological plausibility. Systematic reviews and meta-analyses were used to assess consistency and magnitude of clinical effects, whereas contemporary diabetes guidelines provided the comparator against which clinically meaningful adjunctive therapy should be judged. Because the article is not a systematic review, it does not report a PRISMA flow diagram, pooled effect calculation, formal risk-of-bias table, or exhaustive search yield.

A source-specific intervention taxonomy was applied during synthesis. Studies were classified as involving palm-derived TRF, annatto-derived δ/γ -tocotrienol, purified or predominantly single-isomer tocotrienol, mixed tocotrienol preparations, or formulations whose botanical provenance was insufficiently specified. This classification was necessary because source heterogeneity is a major source of interpretive uncertainty in the literature [15,20].

Thematic synthesis proceeded through nine domains: glycemic control; insulin resistance and glucose transport; oxidative and mitochondrial biology; inflammatory pathways; lipid and adipokine signaling; miRNA regulation; diabetic kidney disease; diabetic neuropathy and vascular injury; and pharmacokinetics/precision response. A final integrative analysis compared the evidence with contemporary person-centered T2DM treatment and developed a translational roadmap emphasizing standardized formulations, pharmacokinetic verification, complication-specific endpoints, and multi-omics responder phenotyping.

Results: Thematic Findings

Clinical glycemic evidence: Promising signals but modest pooled effects

The most direct evidence that tocotrienols can modify glycemic physiology comes from the randomized controlled trial by Mahjabeen et al. participants with T2DM receiving oral

hypoglycemic agents were randomized to 250 mg/day δ -tocotrienol or placebo for 24 weeks. Relative to placebo, the tocotrienol group showed reductions in plasma glucose, insulin, HOMA-IR, and HbA1c, with an HbA1c mean difference of approximately -0.53 percentage points. The same intervention simultaneously reduced malondialdehyde, hs-CRP, TNF- α , and IL-6, suggesting that the glycemic signal occurred in parallel with changes in oxidative and inflammatory biology rather than in isolation [16].

However, pooled evidence is less dramatic. Phang et al. analyzed 10 randomized controlled trials and reported a mean HbA1c reduction of approximately -0.23 percentage points after TRF supplementation. Importantly, subgroup analysis suggested stronger effects in interventions lasting less than six months and in patients with diabetes duration below 10 years. Blood pressure and hs-CRP did not show significant pooled improvement. These results suggest that tocotrienols may have genuine glycemic biological activity, but the magnitude is heterogeneous and likely influenced by disease duration, intervention composition, and study design [20].

A broader meta-analysis by Li et al., which included individuals with varied health conditions rather than T2DM alone, did not find consistent effects on HbA1c, fasting plasma glucose, inflammatory biomarkers, or several anthropometric endpoints. The difference between this broader analysis and the T2DM-specific synthesis reinforces the importance of population phenotype: metabolic effects that are small or absent in heterogeneous populations may become detectable in individuals with greater baseline dysregulation, but such apparent effect modification requires prospective confirmation rather than post hoc interpretation [21].

Prediabetes provides an additional window into timing. Suleman et al. reported significant improvements in fasting glucose, HbA1c, insulin, and HOMA-IR after 12 weeks of 300 mg/day δ -tocotrienol in individuals with prediabetes. Although the trial was relatively small and should not be extrapolated directly to established T2DM, it is consistent with the hypothesis that tocotrienol-mediated insulin sensitization may be more visible before advanced β -cell failure develops [39].

Insulin resistance as a central mechanistic bridge

Improvement in insulin resistance is a plausible mechanism linking tocotrienol exposure to lower glucose concentrations. If peripheral insulin action improves, skeletal-muscle glucose uptake may increase and adipose lipolysis may decline. Reduced free fatty acid flux can in turn reduce hepatic insulin resistance and ectopic lipid accumulation. This metabolic cascade could improve fasting glucose and insulin concentrations without requiring a direct pharmacological effect on β -cell insulin secretion. The same systems view is supported by contemporary analyses of diabetes heterogeneity, which emphasize that insulin resistance interacts with β -cell reserve, inflammation, adiposity, and other pathophysiological hallmarks rather than operating as an isolated defect [4,23].

The available human evidence supports this hypothesis but does not establish causality. Mahjabeen et al. observed simultaneous reductions in insulin and HOMA-IR, while the prediabetes trial reported a similar directional pattern. Yet HOMA-IR is an indirect fasting surrogate and cannot separate hepatic from peripheral insulin sensitivity. Future studies should incorporate oral glucose tolerance modeling, C-peptide measures, continuous glucose monitoring, and, in mechanistic substudies, glucose clamp or isotope tracer methods. Such designs would clarify whether tocotrienols primarily influence hepatic insulin action, skeletal-muscle glucose disposal, adipose lipolysis, or multiple compartments simultaneously [16,39].

Preclinical evidence is consistent with multi-organ effects. In high-fat-diet mice, annatto-derived tocotrienols improved glucose homeostasis and altered adipose cytokines while also modifying gut microbial composition, including an increase in *Akkermansia muciniphila*. Although these findings cannot be translated directly to clinical efficacy, they demonstrate that tocotrienol-induced metabolic improvement could involve adipose, intestinal, microbial, and pancreatic interactions rather than a single antioxidant mechanism [40].

Oxidative stress: Strong biological rationale, inconsistent clinical generalization

Tocotrienols are potent lipid-phase antioxidants, but the clinical significance of this property requires careful interpretation. In the Mahjabeen T2DM trial, malondialdehyde decreased significantly, consistent with reduced lipid peroxidation. Palm-derived TRF studies in diabetic complications also arise from a mechanistic

rationale involving oxidative injury. Nevertheless, the meta-analysis by Khor et al. showed no consistent pooled reductions in IL-6, TNF- α , or malondialdehyde across tocotrienol trials; the apparent reduction in CRP was largely driven by a study using δ -tocotrienol rather than mixed preparations [41].

This inconsistency is informative rather than disappointing. Oxidative-stress biomarkers vary according to disease state, specimen, laboratory method, baseline antioxidant status, obesity, medication, and duration of intervention. A person with high oxidative burden may have more biological room for improvement than someone with relatively normal baseline values. In addition, if systemic exposure differs markedly across formulations, nominally similar tocotrienol doses may produce different redox effects. These considerations argue for baseline phenotype stratification and pharmacokinetic measurement rather than abandoning oxidative stress as a mechanistic domain.

The relationship between oxidative biology and T2DM complications also justifies a broader endpoint strategy. Mitochondrial ROS contribute to endothelial dysfunction, β -cell damage, nerve injury, and kidney disease. A compound that modestly reduces systemic oxidative stress might have little effect on HbA1c yet still influence organ-specific outcomes; conversely, improvement in circulating oxidative biomarkers may not translate into tissue protection. Clinical trials therefore need both molecular and organ-level endpoints [24,25,30].

Figure 2 integrates the principal pathogenic processes of T2DM with the sites at which tocotrienols could plausibly exert

FIGURE 2 Integrated T2DM pathogenic network and putative tocotrienol action nodes




Figure 2: Integrated T2DM pathogenic network and putative tocotrienol action nodes.

Source: Author's synthesis based on refs. [6,16,24,25,27,28,30,33].

metabolic effects. The diagram illustrates why changes in glucose, inflammatory biomarkers, and oxidative stress may reflect interconnected rather than independent effects without implying that every pathway has been clinically validated.

The network highlights why the conventional phrase “antioxidant supplement” may be too restrictive. Tocotrienols could theoretically alter oxidative stress directly, but reduced oxidative injury may also arise secondarily from lower glucose exposure, less lipotoxicity, or improved mitochondrial function. Conversely, suppression of inflammatory signaling could improve insulin action. Current trials cannot resolve these directions of causality, which is why mechanistic multi-omics studies are needed alongside standard glycemic endpoints.

Inflammation, NF-κB, and metabolic signaling

The anti-inflammatory hypothesis is supported by the δ -tocotrienol T2DM trial, where hs-CRP, TNF- α , and IL-6 declined alongside improved glycemic control. Tocotrienols have been reported experimentally to interfere with NF- κ B-related signaling, which could theoretically reduce transcription of inflammatory mediators that impair insulin action. The NLRP3 inflammasome provides another relevant node because it connects nutrient and oxidative stress to IL-1 β and IL-18 signaling and has been implicated in endothelial dysfunction and macrovascular complications [16,28,29].

Nevertheless, meta-analytic inconsistency prevents a categorical conclusion that tocotrienols are clinically effective systemic anti-inflammatory therapies. In the Khor analysis, several inflammatory outcomes were unchanged when trials were pooled. Differences among δ -rich annatto formulations, mixed palm TRF, and other

preparations could partly explain this variability, but baseline inflammatory phenotype and concurrent medications may be equally important. Modern studies should therefore prespecify whether inflammation is a mechanistic mediator, treatment-response biomarker, or secondary exploratory endpoint rather than measuring cytokines without a causal framework [15,41].

miRNA signaling: a particularly novel but preliminary domain

The miRNA findings reported by Mahjabeen et al. distinguish the tocotrienol literature from many conventional nutraceutical studies. The investigators reported more than twofold downregulation of miR-375, miR-34a, and miR-21 and upregulation of miR-126 and miR-132 after δ -tocotrienol supplementation. These miRNAs have plausible relevance to β -cell biology, metabolic stress, inflammation, endothelial function, and insulin-related signaling, which suggests that tocotrienol exposure might influence post-transcriptional regulation in addition to conventional biochemical pathways [16].

Yet the precision-medicine interpretation should remain cautious. A large evidence synthesis of more than 15,000 individuals found dozens of dysregulated miRNAs in T2DM but also considerable tissue and blood-fraction specificity. Sixteen miRNAs emerged as higher-priority biomarker candidates, including miR-126-3p, but no single circulating miRNA has achieved sufficient consistency to function as a stand-alone clinical marker. Differences in sample preparation, hemolysis, normalization, sequencing or PCR platforms, disease duration, medications, and tissue origin substantially affect results [42–44]. Nutritional-genomics research further indicates that dietary components can modulate miRNAs involved in insulin signaling, providing a broader mechanistic rationale for studying food-derived bioactives within a precision-

FIGURE 3 Exploratory tocotrienol-miRNA-metabolic signaling framework




Figure 3: Exploratory tocotrienol-miRNA-metabolic signaling framework.

Source: Author's synthesis based on refs. [16,42–44,46].

nutrition framework [45].

Epigenetic heterogeneity extends beyond miRNAs. DNA methylation studies implicate genes such as TXNIP, ABCG1, PPARGC1A, and SREBF1 in T2DM, while mitochondrial epigenetic alterations may contribute to metabolic dysfunction. These findings support the biological plausibility of an epigenetic responder phenotype but also demonstrate that the field is not ready to use a small miRNA panel to determine who should receive tocotrienols. Replication in independent, source-specific trials is essential [26,46,47].

Figure 3 summarizes the exploratory miRNA relationships that distinguish this tocotrienol–T2DM evidence base. These relationships are presented as hypothesis-generating biological signals rather than validated clinical pathways or treatment-selection biomarkers.

The figure emphasizes that miRNAs could play three different roles that must not be conflated: they might mediate tocotrienol action, they might reflect downstream metabolic improvement without causing it, or they might eventually function as predictive biomarkers of response. Distinguishing among these possibilities requires repeated longitudinal measurement and mediation analysis rather than simple pre–post expression comparisons.

Diabetic kidney disease: Evidence for organ-specific activity

Palm-derived Tocovid provides some of the most clinically interesting evidence because studies have assessed kidney outcomes rather than glucose control alone. In a phase IIb randomized trial, 59 participants with diabetic kidney disease received 400 mg/day tocotrienol-rich vitamin E or placebo for 12 months. Tocovid was associated with lower serum creatinine and higher eGFR in selected analyses, particularly among participants with stage 3 chronic kidney disease, but did not significantly improve UACR, TGF- β 1, or VEGF-A. These mixed outcomes suggest possible renal biological activity while simultaneously demonstrating why no single renal biomarker is sufficient to establish nephroprotection [17].

An earlier phase IIa study similarly reported improvement in serum creatinine and eGFR after Tocovid supplementation, with persistent differences in creatinine after washout, while HbA1c, blood pressure, UACR, and several mechanistic biomarkers did not change significantly. Interestingly, subgroup findings suggested that baseline vitamin E status might modify response, raising the possibility that micronutrient status could become part of a precision-responder framework. However, subgroup analyses from small trials should be regarded as hypothesis-generating [48].

These findings are clinically relevant because contemporary diabetic kidney-disease management uses treatments with demonstrated effects on eGFR decline, kidney failure, heart failure, and cardiovascular outcomes. SGLT2 inhibitors, renin–angiotensin system blockade, and other evidence-based therapies establish a demanding benchmark for adjunctive nutraceuticals. A future palm-TRF renal trial should therefore evaluate eGFR slope,

albuminuria, cystatin C, kidney-injury biomarkers, and ideally longer-term renal outcomes against a standardized contemporary background regimen rather than testing tocotrienols as isolated therapy [12].

Diabetic peripheral neuropathy: Objective physiological signals

Palm-derived tocotrienol studies of peripheral neuropathy provide another example in which organ-specific endpoints may reveal effects not captured by HbA1c. An eight-week multicenter phase II trial reported improved conduction velocities in median, sural, and tibial nerves after Tocovid supplementation together with increased nerve growth factor. These findings were followed by a longer 12-month randomized study in which median and sural sensory-nerve conduction velocities improved compared with placebo, although the differences disappeared after six months of washout and several serum biomarkers did not change [18,19].

The neuropathy data are valuable because nerve conduction studies are more objective than symptom scores alone. However, a modest improvement in velocity does not by itself establish prevention of ulceration, falls, pain, disability, or long-term neurological deterioration. Future studies should combine electrophysiology with validated symptom and functional measures, small-fiber assessments, quality of life, and clinically meaningful complication endpoints. Recent biomarker reviews likewise emphasize that neuropathy, nephropathy, and retinopathy require multidimensional assessment because glycation, oxidative stress, inflammation, endothelial dysfunction, angiogenesis, and non-coding RNAs capture different aspects of microvascular injury [49].

Cardiovascular and metabolic-syndrome evidence

Cardiovascular disease remains the major cause of mortality in T2DM, which makes endothelial and lipid effects clinically relevant. A recent 2026 review synthesized mechanistic and clinical evidence suggesting that TRF may influence ROS, NF- κ B, HMG-CoA reductase, nitric-oxide bioavailability, adhesion molecules, PPAR-related signaling, insulin sensitivity, and lipid metabolism. This provides a coherent mechanistic rationale for cardiovascular investigation but does not substitute for outcome trials [27].

In metabolic syndrome, combined δ -tocotrienol and resveratrol supplementation improved several cardiometabolic risk factors, including fasting glucose and triglycerides. Because the intervention contained two bioactive compounds, however, its effects cannot be attributed specifically to tocotrienol. Such combination studies are informative for translational nutraceutical development but should be kept analytically separate from single-agent evidence [50].

Palm-specific evidence should also be distinguished from dietary palm oil exposure. Palm TRF is a concentrated minor-component preparation and should not be treated as equivalent to consumption of palm oil as a culinary fat. Whole-food fatty-acid exposure, isolated TRF, annatto-derived tocotrienol, and pharmacologically

formulated tocotrienols are different interventions with different dose and metabolic contexts.

Discussion and Critical Analysis

Tocotrienols as multi-node metabolic modulators

The central synthesis of the available evidence is that tocotrienols are more appropriately described as candidate multi-node metabolic modulators than as simple antioxidants. The glycemic, insulin-resistance, inflammatory, oxidative, miRNA, renal, and nerve conduction signals do not fit comfortably within a single free-radical-scavenging mechanism. Instead, they suggest several interconnected possibilities: improved insulin sensitivity may reduce glucose and lipid stress; reduced oxidative stress may improve insulin signaling and endothelial function; NF- κ B modulation may reduce inflammatory interference with metabolic pathways; and changes in regulatory miRNAs may reflect or contribute to broader transcriptional adaptation [14,16,27].

This systems interpretation also explains why clinical outcomes may not move in parallel. HbA1c could improve without a detectable fall in hs-CRP, nerve conduction could improve without HbA1c changing, or eGFR could improve without albuminuria declining. The correct response to this heterogeneity is not to select only favorable endpoints but to determine whether different outcomes arise through distinct biological pathways, chance, measurement variability, or participant phenotype.

The source-isoform problem

Botanical provenance is arguably the most important methodological issue in this literature. The Mahjabeen trial is often cited as evidence for tocotrienols in diabetes, but it should not be described as direct evidence for palm-derived TRF. Conversely, Tocovid kidney and neuropathy trials are relevant to palm-derived preparations but did not reproduce the same pattern of glycemic and inflammatory effects. This distinction suggests that source, isoform composition, formulation, or clinical phenotype may materially modify response [16,17,19].

A future article or meta-analysis that collapses palm TRF and annatto δ -tocotrienol into one undifferentiated intervention risks obscuring biologically meaningful heterogeneity. At minimum, future studies should report milligram quantities of each tocotrienol isoform, tocopherol content, excipients, carrier oil, dosing relative to meals, and plasma concentrations. Sharif et al.'s pharmacokinetic review supports the importance of this approach because annatto and palm formulations differ in bioavailability characteristics [36].

Statistical significance versus clinically meaningful glucose lowering

A pooled HbA1c reduction of approximately 0.23 percentage points demonstrates that an intervention may be biologically active, but its clinical interpretation requires context. Established glucose-lowering medications often produce substantially larger HbA1c reductions, and contemporary therapy is chosen not only for glucose lowering but also for weight, cardiovascular, and kidney effects. Tocotrienols therefore should not be evaluated

according to whether they can “compete” with metformin, GLP-1 receptor agonists, SGLT2 inhibitors, or dual incretin therapy. Their credible clinical niche, if one exists, would be incremental benefit as an adjunct [10,11,20].

This reframing changes the research question. Instead of asking whether tocotrienols lower glucose, future trials should ask whether adding standardized palm TRF to optimized standard care improves glycemic variability, insulin resistance, organ-specific biomarkers, medication intensification, quality of life, or complication trajectories without causing adverse effects or interactions. This is a much more demanding but clinically relevant standard [10,51].

Disease duration and β -cell reserve as potential response modifiers

The subgroup signal indicating stronger HbA1c improvement among individuals with shorter diabetes duration deserves particular attention. Shorter disease duration is generally associated with greater residual β -cell reserve and greater potential for metabolic remission or improvement. If tocotrienols act mainly through insulin sensitization or reduction of metabolic stress, their glycemic effect may become progressively attenuated as β -cell failure advances [7,20].

This hypothesis should be tested prospectively. Future trials could stratify participants according to diabetes duration, fasting C-peptide, stimulated C-peptide, baseline insulin resistance, and insulin use. A demonstration that response varies systematically with β -cell reserve would move tocotrienol research significantly closer to precision therapy.

Precision nutraceutical therapy

Precision nutrition seeks to replace average population response with individualized prediction based on phenotype, genotype, biomarkers, diet, microbiome, and other personal characteristics. This framework is highly relevant because tocotrienol clinical effects appear heterogeneous. Baseline HbA1c, diabetes duration, obesity, renal function, vitamin E status, inflammatory burden, oxidative stress, diet, medication profile, and tocotrienol pharmacokinetic exposure could all theoretically influence response [52,53]. State-of-the-art precision-medicine frameworks further argue that clinically useful personalization requires validated measures of heterogeneity, reproducible biomarkers, external validation, and explicit comparison with current standards of care rather than post hoc identification of apparent responders [5,51].

Yet precision nutrition should not become a justification for explaining away negative findings. The correct approach is prospective prediction. Candidate responder variables should be prespecified, measured before intervention, and tested for interaction with treatment. Only replicated effect modification should be used to define a tocotrienol-responsive phenotype.

Multi-omics technologies could accelerate this process.

Metabolomic studies have identified amino acids, acylcarnitines, ceramides, glycerolipids, and other metabolites associated with incident T2DM, while broader multi-omics frameworks integrate genomics, epigenomics, transcriptomics, proteomics, microbiomics, and metabolomics. Such approaches are increasingly being applied to precision diabetes pharmacotherapy and could be adapted to nutraceutical response research [54-57].

Proposed tocotrienol responder phenotype

A provisional responder framework can be constructed from current evidence. A **metabolically responsive phenotype** might include relatively short diabetes duration, preserved β -cell reserve, substantial insulin resistance, and suboptimal but not extreme hyperglycemia. An **oxidative-inflammatory phenotype** could include high baseline lipid peroxidation or inflammatory markers, creating greater potential for measurable redox change. A **cardiorenal phenotype** might derive more benefit through vascular or renal pathways than through HbA1c reduction, while a **low-exposure phenotype** could appear clinically unresponsive because of poor absorption rather than biological resistance.

These categories are hypotheses, not validated treatment classifications. Precision-subclassification research in T2DM has shown that reproducible metabolic subtypes exist, but evidence that matching specific therapies to these subtypes improves outcomes remains incomplete. Tocotrienol research should learn from this field and avoid premature personalization claims [3].

miRNAs as candidate treatment-response biomarkers [38,41]

Among potential precision biomarkers, miRNAs are particularly

attractive because they can reflect regulatory changes across tissues. However, current evidence supports using them as exploratory mechanistic indicators rather than clinical decision tools. The specific miRNAs altered after δ -tocotrienol treatment overlap only partly with the strongest candidates emerging from large T2DM biomarker meta-analyses, and differences in specimen processing can materially change results [42,43].

A next-generation study should measure miRNAs at baseline and multiple follow-up points, quantify tocotrienol plasma exposure, and determine whether miRNA changes precede or follow metabolic improvement. If a baseline miRNA signature predicts HbA1c or organ response independently of conventional clinical variables, it could then be validated in an external cohort [42,45].

Tocotrienols within contemporary T2DM care

The clinical environment has changed substantially since many tocotrienol studies were designed. Modern person-centered T2DM management prioritizes cardiovascular and kidney protection, weight control, avoidance of hypoglycemia, and treatment burden in addition to HbA1c. For adults with established or high cardiovascular risk, heart failure, or chronic kidney disease, SGLT2 inhibitors and/or GLP-1-based therapies with demonstrated outcome benefits are recommended irrespective of baseline HbA1c in appropriate clinical settings [11,58].

There is currently no adequate evidence that tocotrienols can replace any therapy with proven cardiovascular, kidney, or mortality benefit. Their scientifically defensible role is therefore investigational and adjunctive. A future palm-TRF trial should

FIGURE 4 Next-generation palm-TRF precision trial architecture




Figure 4: Proposed next-generation palm-TRF precision trial architecture.

Source: Author's synthesis based on refs. [3,15,20,36,52,54,55,57].

preserve evidence-based background treatment and ask whether TRF adds a measurable benefit beyond that baseline.

Figure 4 translates the identified evidence gaps into a next-generation trial architecture for palm-derived TRF in precision T2DM management. The framework separates intervention standardization, systemic exposure, metabolic response, organ protection, and responder identification so that each claim can be tested independently.

The design explicitly separates dose from exposure and glucose lowering from organ protection. It would also allow apparently discordant outcomes—such as improvement in kidney function without HbA1c reduction—to be analyzed as potentially distinct treatment pathways rather than statistical anomalies.

Research priorities

The first priority is **intervention standardization**. Botanical source, individual tocotrienol content, tocopherol content, delivery vehicle, and pharmacokinetic exposure should become mandatory reporting items. Without these data, replication is difficult and meta-analysis can produce misleading averages.

The second priority is adequate duration and sample size. Short trials are useful for mechanistic signals but cannot establish sustained glycemic efficacy, preservation of β -cell function, kidney protection, neuropathy progression, or cardiovascular benefit. Multicenter studies lasting at least 12 months would provide a more appropriate platform for evaluating durability, safety, adherence, and medication intensification [5,20].

The third priority is modern glycemic assessment. HbA1c should remain important, but continuous glucose monitoring could add time-in-range, glycemic variability, and postprandial profiles. These outcomes may reveal metabolic effects that fasting glucose does not capture and are increasingly integrated into contemporary diabetes care [11].

The fourth priority is organ-specific endpoints. Kidney trials should use eGFR slope, albuminuria, and clinically validated renal markers; neuropathy trials should combine nerve conduction with symptoms and functional outcomes; vascular studies should use standardized endothelial and cardiovascular measures. The evidence hierarchy should progress from biomarkers toward patient-relevant outcomes rather than repeatedly reproducing small biochemical trials [12,49].

Finally, precision-response modeling should be prospective. Phenotype, pharmacokinetics, metabolomics, epigenetics, and miRNA profiles should be measured within the same randomized trial, allowing researchers to determine whether molecular signatures genuinely predict treatment response. Precision nutrition literature increasingly supports individualized approaches, but current evidence also emphasizes methodological heterogeneity and the need for external validation [3,52,53,57].

Conclusion

Tocotrienols occupy an intriguing position at the intersection of nutritional biochemistry, metabolic medicine, and precision therapeutics. Their biological properties extend beyond conventional free-radical scavenging and plausibly intersect with insulin resistance, mitochondrial redox balance, inflammatory signaling, lipid metabolism, endothelial dysfunction, advanced glycation, and post-transcriptional regulation. Human studies provide evidence of biological activity, including modest glycemic improvement in some T2DM populations, changes in oxidative and inflammatory biomarkers, altered circulating miRNAs, and organ-specific signals involving kidney function and nerve conduction.

At the same time, the evidence does not justify describing palm-derived tocotrienols as established antidiabetic therapy. The strongest integrated glycemic-inflammatory-miRNA evidence comes from an annatto-derived δ -rich preparation, whereas direct palm-TRF evidence is concentrated more heavily in diabetic kidney disease, neuropathy, and broader cardiometabolic research. Source-specific interpretation is therefore indispensable.

The pooled HbA1c effect appears modest and heterogeneous, and current studies do not establish preservation of β -cell function, prevention of cardiovascular events, prevention of kidney failure, durable medication de-intensification, or reduced mortality. Tocotrienols should consequently be positioned as investigational adjunctive nutraceuticals rather than substitutes for therapies with demonstrated glycemic and cardiorenal benefits.

The next phase of research should move beyond repeated biomarker trials. Standardized palm-derived formulations, quantitative isoform characterization, pharmacokinetic verification, contemporary background therapy, longer follow-up, continuous glucose monitoring, organ-specific outcomes, and integrated multi-omics are needed. Such studies could determine whether response is concentrated among individuals with shorter diabetes duration, preserved β -cell reserve, insulin-resistant phenotypes, elevated oxidative-inflammatory burden, low baseline vitamin E status, or favorable tocotrienol exposure.

The key scientific question is therefore no longer simply whether tocotrienols lower glucose. It is whether a reproducible biological and clinical responder phenotype exists—and whether a precisely characterized palm-derived tocotrienol intervention can provide meaningful incremental benefit within modern, person-centered diabetes care.

References

1. GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: A systematic analysis for the Global Burden of Disease Study 2021. *The Lancet*. 2023; 402: 203-234.
2. Ke C, Narayan KMV, Chan JCN, et al. Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations. *Nat Rev Endocrinol*. 2022;

18: 413-432.

3. Misra S, Wanger R, Ozkan B, et al. Precision subclassification of type 2 diabetes: A systematic review. *Commun Med*. 2023; 3: 138.
4. Leslie RD, Franks PW, Nadeau KJ, et al. Understanding diabetes heterogeneity: key steps towards precision medicine in diabetes. *Lancet Diabetes Endocrinol*. 2023; 11: 848-860.
5. Franks PW, Rich SS, Linder B, et al. A research roadmap to address the heterogeneity of diabetes and advance precision medicine. *J Clin Endocrinol Metab*. 2025; 110: 601-610.
6. Galicia-Garcia U, Benito Vicente A, Jebari S, et al. Pathophysiology of type 2 diabetes mellitus. *Int J Mol Sci*. 2020; 21: 6275.
7. Wysham C, Shubrook JH. Beta-cell failure in type 2 diabetes: Mechanisms, markers, and clinical implications. *Postgrad Med*. 2020; 132: 676-686.
8. Ikegami H, Babaya N, Noso S. β -Cell failure in diabetes: Common susceptibility and mechanisms shared between type 1 and type 2 diabetes. *J Diabetes Investig*. 2021; 12: 1526-1539.
9. Charles MA, Leslie RD. Diabetes: Concepts of β -cell organ dysfunction and failure would lead to earlier diagnoses and prevention. *Diabetes*. 2021; 70: 2444-2456.
10. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022: A consensus report by the ADA and EASD. *Diabetes Care*. 2022; 45: 2753-2786.
11. American Diabetes Association Professional Practice Committee for Diabetes. 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes-2026. *Diabetes Care*. 2026; 49: 183-215.
12. de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: A consensus report by the American Diabetes Association and Kidney Disease: Improving Global Outcomes. *Diabetes Care*. 2022; 45: 3075-3090.
13. Szezyzyk K, Chojnacka A, Górnicka M. Tocopherols and tocotrienols—bioactive dietary compounds; what is certain, what is doubtful?. *Int J Mol Sci*. 2021; 22: 6222.
14. Ranasinghe R, Mathai M, Zulli A. Revisiting the therapeutic potential of tocotrienol. *Biofactors*. 2022; 48: 813-856.
15. Looi AD, Palanisamy UD, Moorthy M, et al. Health benefits of palm tocotrienol-rich fraction: A systematic review of randomized controlled trials. *Nutr Rev*. 2025; 83: 307-328.
16. Mahjabeen W, Khan DA, Mirza SA, et al. Effects of delta-tocotrienol supplementation on glycemic control, oxidative stress, inflammatory biomarkers and miRNA expression in type 2 diabetes mellitus: A randomized control trial. *Phytother Res*. 2021; 35: 3968-3976.
17. Koay YY, Jie TGC, Phang SCW, et al. A phase IIb randomized controlled trial investigating the effects of tocotrienol-rich vitamin E on diabetic kidney disease. *Nutrients*. 2021; 13: 258.
18. Ng YT, Phang SCW, Jie TGC, et al. The effects of tocotrienol-rich vitamin E (Tocovid) on diabetic neuropathy: A phase II randomized controlled trial. *Nutrients*. 2020; 12: 1522.
19. Chuar PF, Phang SCW, Ng YT, et al. Tocotrienol-rich vitamin E (Tocovid) improved nerve conduction velocity in type 2 diabetes mellitus patients in a phase II double-blind, randomized controlled clinical trial. *Nutrients*. 2021; 13: 3770.
20. Phang SCW, Ahmad B, Abdul Kadir, et al. Effects of tocotrienol-rich fraction supplementation in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. *Adv Nutr*. 2023; 14: 1159-1169.
21. Li F, Soltanieh S, Zanghelini F, et al. The effects of tocotrienols intake on obesity, blood pressure, inflammation, liver and glucose biomarkers: A meta-analysis of randomized controlled trials. *Crit Rev Food Sci Nutr*. 2022; 62: 7154-7167.
22. Lima JEBF, Moreira NCS, Sakamoto Hojo ET. Mechanisms underlying the pathophysiology of type 2 diabetes: From risk factors to oxidative stress, metabolic dysfunction, and hyperglycemia. *Mutat Res Genet Toxicol Environ Mutagen*. 2022; 875: 503437.
23. Datta D, Kundu R, Basu R, et al. Pathophysiological hallmarks in type 2 diabetes heterogeneity. *Diabetol Int*. 2025; 16: 201-222.
24. Yarıbeygi H, Sathyapalan T, Sahebkar A, et al. Molecular mechanisms linking oxidative stress and diabetes mellitus. *Oxid Med Cell Longev*. 2020; 9: 8609213.
25. Apostolova N, Vezza T, Muntane J, et al. Mitochondrial dysfunction and mitophagy in type 2 diabetes: Pathophysiology and therapeutic targets. *Antioxid Redox Signal*. 2023; 39: 278-320.
26. Low HC, Chilian WM, Ratnam W, et al. Changes in mitochondrial epigenome in type 2 diabetes mellitus. *Br J Biomed Sci*. 2023; 80: 10884.
27. Ali M, Sheikh Abdul Kadir SH, Ibrahim E, et al. Tocotrienol-rich fraction of vitamin E in diabetes and cardiovascular disease: From molecular mechanisms to clinical application. *Int J Cardiol Cardiovasc Risk Prev*. 2026; 30: 200686.
28. Gora IM, Ciechanowska A, Ladyzynski P. NLRP3 inflammasome at the interface of inflammation, endothelial dysfunction, and type 2 diabetes. *Cells*. 2021; 10: 314.
29. Karamitsos K, Oikonomou E, Theofilis P, et al. The role of NLRP3 inflammasome in type 2 diabetes mellitus and its macrovascular complications. *J Clin Med*. 2025; 14: 4606.
30. An Y, Xu BT, Wan SR, et al. The role of oxidative stress in diabetes mellitus-induced vascular endothelial dysfunction. *Cardiovasc Diabetol*. 2023; 22: 237.
31. Ma CX, Ma XN, Guan CH, et al. Cardiovascular disease in type 2 diabetes mellitus: Progress toward personalized management. *Cardiovasc Diabetol*. 2022; 21: 74.
32. Cheng JX, Yu K. New discovered adipokines associated with the pathogenesis of obesity and type 2 diabetes. *Diabetes Metab Syndr Obes*. 2022; 15: 2381-2389.

33. Khalid M, Petroianu G, Adem A. Advanced glycation end products and diabetes mellitus: Mechanisms and perspectives. *Biomolecules*. 2022; 12: 542.
34. Salazar J, Navarro C, Ortega A, et al. Advanced glycation end products: New clinical and molecular perspectives. *Int J Environ Res Public Health*. 2021; 18: 7236.
35. Indyk D, Bronowicka Szydelko A, Gamian A, et al. Advanced glycation end products and their receptors in serum of patients with type 2 diabetes. *Sci Rep*. 2021; 11: 3264.
36. Sharif M, Khan DA, Farhat K, et al. Pharmacokinetics and bioavailability of tocotrienols in healthy human volunteers: A systematic review. *J Pak Med Assoc*. 2023; 73: 603-610.
37. Mohd Zaffarin AS, Ng SF, Hassan H, et al. Pharmacology and pharmacokinetics of vitamin E: Nanoformulations to enhance bioavailability. *Int J Nanomedicine*. 2020; 15: 9961-9974.
38. Ooi AG, Yuen KH, Chu CC, et al. Oral delivery of tocotrienols: Addressing pharmacokinetic challenges with formulation-based strategies. *Lipids*. 2026.
39. Suleman F, Khan DA, Pervez MA, et al. Effects of delta-tocotrienol supplementation on glycaemic control in individuals with prediabetes: A randomized controlled study. *J Pak Med Assoc*. 2022; 72: 4-7.
40. Chung E, Elmassry MM, Kottapalli P, et al. Metabolic benefits of annatto-extracted tocotrienol on glucose homeostasis, inflammation, and gut microbiome. *Nutr Res*. 2020; 77: 97-107.
41. Khor BH, Tiong HC, Tan SC, et al. Effects of tocotrienols supplementation on markers of inflammation and oxidative stress: A systematic review and meta-analysis of randomized controlled trials. *PLoS One*. 2021; 16: 0255205.
42. Zhu H, Leung SW. MicroRNA biomarkers of type 2 diabetes: Evidence synthesis from meta-analyses and pathway modelling. *Diabetologia*. 2023; 66: 288-299.
43. Afsharmanesh MR, Mohammadi Z, Mansourian AR, et al. A review of micro RNAs changes in T2DM in animals and humans. *J Diabetes*. 2023; 15: 649-664.
44. Kariuki D, Aouizerat BE, Asam K, et al. MicroRNA biomarkers target genes and pathways associated with type 2 diabetes. *Diabetes Res Clin Pract*. 2023; 203: 110868.
45. Capetini VC, Quintanilha BJ, Garcia BREV, et al. Dietary modulation of microRNAs in insulin resistance and type 2 diabetes. *J Nutr Biochem*. 2024; 133: 109714.
46. Ling C, Bacos K, Rönn T. Epigenetics of type 2 diabetes mellitus and weight change—a tool for precision medicine?. *Nat Rev Endocrinol*. 2022; 18: 433-448.
47. Nadiger N, Veed JK, Nataraj PC, et al. DNA methylation and type 2 diabetes: A systematic review. *Clin Epigenetics*. 2024; 16: 67.
48. Tan GCJ, Quinn Tan SM, Wen Phang SC, et al. Tocotrienol-rich vitamin E improves diabetic nephropathy and persists 6-9 months after washout: A phase IIa randomized controlled trial. *Ther Adv Endocrinol Metab*. 2020; 11: 2042018819895462.
49. Wang J, Song X, Xia Z, et al. Serum biomarkers for predicting microvascular complications of diabetes mellitus. *Expert Rev Mol Diagn*. 2024; 24: 703-713.
50. Fatima S, Khan DA, Aamir M, et al. δ -Tocotrienol in combination with resveratrol improves the cardiometabolic risk factors and biomarkers in patients with metabolic syndrome: A randomized controlled trial. *Metab Syndr Relat Disord*. 2023; 21: 25-34.
51. Franks PW, Sargent JL. Diabetes and obesity: leveraging heterogeneity for precision medicine. *Eur Heart J*. 2024; 45: 5146-5155.
52. Antwi J. Precision nutrition to improve risk factors of obesity and type 2 diabetes. *Curr Nutr Rep*. 2023; 12: 679-694.
53. Arias-Marroquín AT, Razo-Olvera FMD, Castañeda-Bernal BM, et al. Personalized versus non-personalized nutritional recommendations/interventions for type 2 diabetes mellitus remission: A narrative review. *Diabetes Ther*. 2024; 15: 749-761.
54. Morze J, Wittenbecher C, Shwingshckl L, et al. Metabolomics and type 2 diabetes risk: An updated systematic review and meta-analysis of prospective cohort studies. *Diabetes Care*. 2022; 45: 1013-1024.
55. Hu C, Jia W. Multi-omics profiling: The way towards precision medicine in metabolic diseases. *J Mol Cell Biol*. 2021; 13: 576-593.
56. Chowdhury S, Faheem SM, Nawaz SS, et al. The role of metabolomics in personalized medicine for diabetes. *Per Med*. 2021; 18: 501-508.
57. Dhieb D, Mustafa D, Hassiba M, et al. Harnessing pharmacomultiomics for precision medicine in diabetes: A comprehensive review. *Biomedicines*. 2025; 13: 447.
58. American Diabetes Association Professional Practice Committee for Diabetes. 10. Cardiovascular disease and risk management: Standards of Care in Diabetes-2026. *Diabetes Care*. 2026; 49: 216-245.